These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37186998)

  • 1. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments.
    Lei H; Duan W; Zhang SQ; Feng Y; Ma M; Yuan B; Xin M
    Bioorg Chem; 2023 Sep; 138():106594. PubMed ID: 37186998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
    Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
    Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Evaluation of Novel 2H-Benzo[e]-[1,2,4]thiadiazine 1,1-Dioxide Derivatives as PI3Kδ Inhibitors.
    Gong YP; Tang LQ; Liu TS; Liu ZP
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31775363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
    Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
    Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):651-656. PubMed ID: 29536777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
    Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
    J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold.
    Ma M; Feng Y; Zhang SQ; Duan W; Gao L; Yuan B; Xin M
    Future Med Chem; 2023 Aug; 15(16):1491-1509. PubMed ID: 37565336
    [No Abstract]   [Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation.
    Tao Q; Chen Y; Liang X; Hu Y; Li J; Fang F; Wang H; Meng C; Liang J; Ma X; Gui S
    Eur J Med Chem; 2020 Apr; 191():112143. PubMed ID: 32078865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and bioactivity evaluation of selenium-containing PI3Kδ inhibitors.
    Gao L; Chuai H; Ma M; Zhang SQ; Zhang J; Li J; Wang Y; Xin M
    Bioorg Chem; 2023 Nov; 140():106815. PubMed ID: 37672953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
    Liu K; Zheng W; Chen Y; Tang M; Li D; Deng D; Yang T; Zhang C; Liu J; Yuan X; Shi M; Li X; Guo Y; Zhou Y; Zhao M; Chen L
    J Med Chem; 2022 Jul; 65(14):9893-9917. PubMed ID: 35831917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors.
    Wang Y; Liu Y; Ge T; Tang J; Wang S; Gao Z; Chen J; Xu J; Gong P; Zhao Y; Liu J; Hou Y
    Bioorg Chem; 2023 Jan; 130():106211. PubMed ID: 36343598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity.
    Teng Y; Li X; Ren S; Cheng Y; Xi K; Shen H; Ma W; Luo G; Xiang H
    Eur J Med Chem; 2020 Dec; 208():112865. PubMed ID: 32987316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation.
    Ma X; Fang F; Tao Q; Shen L; Zhong G; Qiao T; Lv X; Li J
    Medchemcomm; 2019 Mar; 10(3):413-420. PubMed ID: 30996859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
    Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.
    Xin M; Hei YY; Zhang H; Shen Y; Zhang SQ
    Bioorg Med Chem Lett; 2017 May; 27(9):1972-1977. PubMed ID: 28325601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.